Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients

Objective Leflunomide is a disease-modifying antirheumatic drug used for treating rheumatoid arthritis (RA). In vitro studies demonstrated that cytochromes P450 (CYPs), mainly CYP1A2 and CYP2C19, might be involved in leflunomide activation. The aim of our study was to investigate whether genetic pol...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical pharmacology 2008-09, Vol.64 (9), p.871-876
Hauptverfasser:	Bohanec Grabar, Petra, Rozman, Blaž, Tomšič, Matija, Šuput, Daša, Logar, Dušan, Dolžan, Vita
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antirheumatic Agents - toxicity Arthritis, Rheumatoid - drug therapy Biological and medical sciences Biomedical and Life Sciences Biomedicine Cytochrome P-450 CYP1A2 - genetics Diarrhea - chemically induced Diseases of the osteoarticular system Dose-Response Relationship, Drug Drug therapy Female Genotype & phenotype Humans Inflammatory joint diseases Isoxazoles - toxicity Male Medical sciences Middle Aged Nausea - chemically induced Pharmacogenetics Pharmacology Pharmacology. Drug treatments Pharmacology/Toxicology Pilot Projects Polymorphism Polymorphism, Genetic Pruritus - chemically induced Rheumatoid arthritis Toxicity Vomiting - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!